Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study

Rheumatology (Oxford). 2023 Sep 1;62(9):e276-e277. doi: 10.1093/rheumatology/kead036.

Authors

Petros P Sfikakis¹, Stylianos Panopoulos¹, Sofia Mavrogeni²

Affiliations

¹ First Department of Propaedeutic and Internal Medicine and Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
² Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.

PMID: 36707992
DOI: 10.1093/rheumatology/kead036

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiomyopathies* / drug therapy
Cardiomyopathies* / etiology
Humans
Lung Diseases, Interstitial*
Pilot Projects
Scleroderma, Systemic* / complications
Scleroderma, Systemic* / drug therapy

Substances

nintedanib